Introduction {#s1}
============

The epithelial to mesenchymal transition (EMT) has been originally described as an essential process of metazoan embryogenesis [@pone.0051136-Hay1]. In the past decade, EMT has been realized as a critical event in carcinoma progression as epithelial tumor cells acquire a mesenchymal phenotype that allows them to detach from the primary tumor and to invade into the local tissue [@pone.0051136-Hay2]. In general, polarized epithelial cells are organized by cell-cell junctions and cell-anchoring complexes to form apical and basolateral surfaces. In contrast, mesenchymal cells form irregularly shaped structures in the absence of tight adhesions to the neighboring cells and reduced cell contact to the substratum. Mesenchymal cells have an elongated shape compared to epithelia and display an anterior-posterior polarity that enables enhanced migration through reduced adhesion forces. While epithelial cells invade collectively in clusters, mesenchymal cells show individual cell movement that allows them to disseminate from bulk cells [@pone.0051136-vanZijl1]. In addition, a partial EMT displaying different levels of E-cadherin expression has been observed that might still lead to collective cell invasion [@pone.0051136-Friedl1].

EMT has been classified into three subtypes [@pone.0051136-Kalluri1]. Type 1 EMT is required for embryogenesis to provide gastrulation and formation of neural crest cells that differentiate into various cell types without systemic spreading. Type 2 EMT is involved in tissue regeneration and fibrosis of different organs such as the kidney, liver, lung and intestine leading to the accumulation of connective tissue. Type 3 EMT associates with a gain in malignancy of carcinoma cells. Neoplastic epithelial cells induced to undergo EMT are frequently localized at the invasive front of the primary tumor and initiate the cascade of tumor cell dissemination by local cell invasion which is followed by the entry into the vasculature. Notably, EMT represents a transient and reversible process that can lead to a mesenchymal to epithelial transition (MET) upon metastatic colonization [@pone.0051136-Kalluri1], . Cycles of EMT and MET are assumed to be involved in metastasis formation at distal sites [@pone.0051136-vanZijl1]. Yet, the molecular basis for the changes in epithelial plasticity by EMT and MET is still an open issue and its role in cancer patients is a matter of debate. Signaling molecules and inducers of type 3 EMT confer the resistance of cancer cells to apoptosis and oncogene-induced senescence as well as chemoresistance [@pone.0051136-Thiery1]. Recent findings indicate that EMT provides mesenchymal cells with stem cell features that enable carcinoma cells to generate metastasis at secondary sites [@pone.0051136-vanZijl1]. These cancer stem cells, also termed cancer initiating cells, share phenotypic and functional characteristics with migratory embryonic cells displaying a mesenchymal phenotype [@pone.0051136-Thiery1].

Profiling of the transcriptome using microarrays has been widely used to elucidate the expression patterns during EMT under different conditions which revealed novel biomarkers and molecular mechanisms from single studies. A meta-analysis usually describes the combination of a large number of studies from different samples and tissues or the comparison of own data with published data [@pone.0051136-Loboda1], [@pone.0051136-Tobin1]. Recent progress in the establishment of gene expression datasets enables to identify new markers and relevant mechanisms which were underestimated in single studies but emerged from a meta-analysis. By now, a plethora of gene expression studies (GES) covering a wide variety of cell types undergoing EMT together with various modes of induction are available. Yet to our knowledge, no meta-analysis dealing with these EMT studies has been performed so far.

Changes in a biological system require a concerted alteration of gene expression sets. Bioinformatic enrichment analysis tools investigate gene expression sets for such changes. These tools examine the overrepresentation of gene sets in comparison to the whole genome, map an input list of genes to biological categories in online databases and statistically assess the overrepresentation of genes for each biological category or annotation such as Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways and gene ontology (GO) terms [@pone.0051136-Huangda1]. The use of several single enrichment tools for the same input list and the consideration of only consistently enriched categories have been reported to be a very promising strategy [@pone.0051136-Rhee1], [@pone.0051136-Lascorz1].

We gathered data from 18 published and independent GES of EMT and extracted gene lists of significantly up- and downregulated genes for cluster analysis. This approach revealed gene clusters according to treatment modalities rather than to cell type. We subsequently extracted an EMT-core list consisting of 130 genes with official gene symbols and names which was further investigated by enrichment analysis with several single enrichment tools. Notably, selected genes from the EMT-core list significantly correlated with impaired pathological complete response (pCR) in breast cancer patients. This analysis proposes that the EMT-core gene list is relevant for the recognition of the molecular mechanisms of EMT. In addition, the cluster analysis shows novel insights into the relationships of EMT processes across different cell types and induction modes.

Results {#s2}
=======

Data collection of gene expression studies (GES) {#s2a}
------------------------------------------------

To assess the similarities between published GES and define a core gene list of human EMT, we analyzed 18 independent GES of EMT. These 18 independent and published GES consisted of 24 datasets in total ([Table 1](#pone-0051136-t001){ref-type="table"}). Several authors reported EMT kinetics of different cell types or dose-dependent effects of EMT inducers within single studies. Nevertheless, only the particular testing point showing the strongest effect or EMT phenotype, as reported by the authors, has been selected. Takahashi *et al.* published two related GES, of which one consisted of two datasets, resulting in three datasets of one independent study [@pone.0051136-Takahashi1]. Taube *et al.* reported 5 datasets published within one GES with similar expression patterns and different modes of EMT induction [@pone.0051136-Taube1]. Processed data (normalized and generally logarithmized data) were downloaded from the Gene expression Omnibus (GEO) and ArrayExpress (AE) databases and annotated with BioConductor and NetAffx. Numerous GES, available on GEO and AE, were excluded as they either did not provide processed data or did not contain replicates or have not been published. Due to the variety of microarray formats as well as different normalization and filtering methods used in the literature, we used processed instead of raw data in order to maintain the quality criteria applied by the authors during the data preprocessing. Two-tailed Student\'s *t*-test was used to compute p-values. Significantly up- and downregulated genes were selected to meet a fold change greater than 2 or lower than 0.5 and a p-value below 0.05.

10.1371/journal.pone.0051136.t001

###### Gene expression studies of EMT used for meta-analysis.

![](pone.0051136.t001){#pone-0051136-t001-1}

  First author                                       Acc.                      Ref.                  Cell type         Cell origin                                          Treatment modality                                               Platform          Samples[\*](#nt101){ref-type="table-fn"}
  ------------------------------------------- ------------------- ------------------------------ ------------------ ----------------- ----------------------------------------------------------------------------------------------- ----------------------- ------------------------------------------
  Ke                                              E-TABM-949           [@pone.0051136-Ke1]          EP156T/EPT2         Prostate                             high cell density[a](#nt102){ref-type="table-fn"}                         Agil WHG 4×44K G4112F                      2
  Andarawewa                                        GSE8240        [@pone.0051136-Andarawewa1]         MCF10A            Breast                              TGF-β+irradiation[a](#nt102){ref-type="table-fn"}                             Affy HTU133A                           3
  Takahashi[c](#nt104){ref-type="table-fn"}    GSE12548/GSE15205    [@pone.0051136-Takahashi1]         ARPE19        Retinal pigment    TGF-β+TNF-α[a](#nt102){ref-type="table-fn"}/TGF-β or TNF-α[a](#nt102){ref-type="table-fn"}        Affy U133Plus2                          3
  Tay                                              GSE13759            [@pone.0051136-Tay1]          HCT116/E1            Colon                           serial transplantation[b](#nt103){ref-type="table-fn"}                            Affy U133A                            3
  Drake                                            GSE14405           [@pone.0051136-Drake1]        PC-3/TEM4-18        Prostate                        transendothelial migration[a](#nt102){ref-type="table-fn"}                        Affy U133Plus2                          2
  Hwang                                            GSE14773           [@pone.0051136-Hwang1]            CRC               Colon                             spheroid formation[a](#nt102){ref-type="table-fn"}                            Affy U133Plus2                          2
  Sartor                                           GSE17708          [@pone.0051136-Sartor1]            A549              Lung                                     TGF-β[a](#nt102){ref-type="table-fn"}                                  Affy U133Plus2                          3
  Papageorgis                                      GSE18070        [@pone.0051136-Papageorgis1]      MCF10CA1h           Breast                               H-Ras+carcinoma[b](#nt103){ref-type="table-fn"}                             Affy U133Plus2                          3
  Hills                                            GSE20247           [@pone.0051136-Hills1]            HK2              Kidney                                 TGF-β+Cpep[a](#nt102){ref-type="table-fn"}                               Illum HWG-6 v3.0                         3
  Leshem                                           GSE22010          [@pone.0051136-Leshem1]         PrEC-hTERT         Prostate                                 AR+T/ERG[a](#nt102){ref-type="table-fn"}                                 Affy HG 1.0 ST                          4
  Micalizzi                                        GSE23655         [@pone.0051136-Micalizzi1]          MCF7             Breast                                 Six1 vector[a](#nt102){ref-type="table-fn"}                                Affy HTU133A                           6
  Maupin                                           GSE23952          [@pone.0051136-Maupin1]           Panc-1           Pancreas                                   TGF-β[a](#nt102){ref-type="table-fn"}                                  Affy U133Plus2                          3
  Taube^d^                                         GSE24202           [@pone.0051136-Taube1]            HMLE             Breast        TGF-β1; Snail1, Twist, Gsc vectors; siRNA against E-Cadherin [a](#nt102){ref-type="table-fn"}       Affy HTU133A                           3
  Baniwal                                          GSE24261          [@pone.0051136-Baniwal1]     PCa C4-2B/Rx2dox      Prostate                               Runx2 vector[a](#nt102){ref-type="table-fn"}                               Illum HR-8 v3.0                         4
  van Zijl                                         GSE26391          [@pone.0051136-vanZijl2]          3p/3sp             Liver                             tumor cell recovery[b](#nt103){ref-type="table-fn"}                           Affy HG 1.0 ST                          2
  Ohashi                                           GSE27424          [@pone.0051136-Ohashi1]         EPC2-hTERT         Esophagus                        Notch3 knock-down (shRNA)[a](#nt102){ref-type="table-fn"}                        Affy U133Plus2                          3
  Hesling                                          GSE28448          [@pone.0051136-Hesling1]         HMEC-TR            Breast                          TGF-β+siRNA against TIFγ[a](#nt102){ref-type="table-fn"}                         Affy U133Plus2                          2
  Wang                                             GSE28799           [@pone.0051136-Wang1]           OVCAR-3             Ovary                             spheroid formation[a](#nt102){ref-type="table-fn"}                            Affy U133Plus2                          3

, lowest number of samples per class (control or test subject).

, *in vitro*;

, *in vivo*;

, consists of two studies with three datasets in total; d, consists of five datasets.

Abbreviations: Affy, Affymetrix; Agil, Agilent; AR, androgen receptor; Illum, Illumina; sh, small hairpin; si, small interfering; T/ERG, TMPRSS2/ERG; TGF, transforming growth factor; TNF, tumor necrosis factor.

GES cluster analysis {#s2b}
--------------------

We generated a matrix containing gene symbols across the analyzed GES (n = 14,113) that are all uniquely reported. Significantly up- and downregulated genes of each GES were transferred into the matrix according to their type of regulation. Upregulated genes were labeled with 1, downregulated genes with −1 and not differentially regulated genes with 0 ([Table S1](#pone.0051136.s004){ref-type="supplementary-material"}). This data distribution consisted of 88.22% not differentially regulated genes and 11.78% up- or downregulated genes and is significantly different to a binomial distribution with those parameters (p\<0.0001). In order to determine a cutoff for the number of GES sharing a particular gene used for cluster analysis, the binomial distribution function provided by R as well as the preliminary hierarchical clustering results of each cutoff option were analyzed (data not shown). From this we decided to investigate the clustering of genes shared between at least 10 datasets (n = 365; p\<0.0001; [Figure 1](#pone-0051136-g001){ref-type="fig"}). In addition, this analysis showed clusters of GES according to the mode of EMT stimulus rather than to cell type ([Figure 2A](#pone-0051136-g002){ref-type="fig"}). Interestingly, a more stringent clustering of genes shared between at least 14 of the analyzed GES datasets provided similar clusters, despite the fact that this list contains only 41 genes ([Figure 2B](#pone-0051136-g002){ref-type="fig"} and [Figure S1](#pone.0051136.s001){ref-type="supplementary-material"}).

![Cluster analysis of genes shared between at least 10 GES datasets shows distinguishable and significant clusters.\
Genes shared between at least 10 out of 24 datasets were used for Manhattan hierarchical clustering. The type of regulation within a particular study was visualized via heatmap. Columns: genes shared between at least 10 datasets (n = 365); rows: analyzed GES (24 datasets in total); green: downregulated genes; red: upregulated genes; black: genes not regulated. GSE: Gene expression omnibus (GEO) series record; E.TABM: ArrayExpress (AE) series record; TGF, transforming growth factor; TNF, tumor necrosis factor.](pone.0051136.g001){#pone-0051136-g001}

![Gene expression studies cluster according to the mode of EMT initiation rather than to cell type.\
The cell type and treatment modality of EMT was annotated and revealed clustering according to the mode of EMT induction. The clustering persisted when genes shared between at least 14 GES datasets were used for the analysis. (A) Hierarchical clustering of 365 genes shared between at least 10 datasets. (B) Hierarchical clustering of 41 genes shared between at least 14 datasets. The legend indicates cell type and treatment modality (right panel). \*, Transcription factor vectors: Runx2, Six1, Snail, Twist and Goosecoid. GSE: Gene expression omnibus (GEO) series record; E.TABM: ArrayExpress (AE) series record; TGF, transforming growth factor; TNF, tumor necrosis factor.](pone.0051136.g002){#pone-0051136-g002}

Generation of the EMT-core gene list {#s2c}
------------------------------------

Based on the cluster analysis of the GES, we aimed to define a meaningful EMT-core gene list which describes the majority of the involved genes across the analyzed GES. The cluster analysis of the genes shared between at least 10 datasets contained 365 genes ([Table S2](#pone.0051136.s005){ref-type="supplementary-material"}). However, it does not show whether a gene is up- or downregulated across different GES. Therefore, the list was filtered to keep only genes which were either up- or downregulated in at least 10 of the GES datasets. The resulting list contained 130 genes of which 67 are up- and 63 are downregulated ([Table 2](#pone-0051136-t002){ref-type="table"} and [Table S3](#pone.0051136.s006){ref-type="supplementary-material"}). This selection of genes could be further classified into five categories ((i) cell adhesion and migration, (ii) development, cell differentiation and proliferation, (iii) angiogenesis and wound healing, (iv) metabolism, (v) others or unclassified) according to single enrichment analysis as described below. Several genes were also present in more than one of those categories ([Table S3](#pone.0051136.s006){ref-type="supplementary-material"}). In conclusion, this resulting EMT-core gene list contains 130 genes which were derived from a multitude of cell types and EMT initiation methods.

10.1371/journal.pone.0051136.t002

###### EMT-core list of 130 genes shared between at least 10 GES datasets.

![](pone.0051136.t002){#pone-0051136-t002-2}

                                                                                                                                                                                Upregulated                                                                                                                                                                                                Downregulated
  --------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Cell adhesion and migration**                            ADAM12, CDH11, CDH2, COL1A1, COL3A1, COL5A1, COL6A1, COL6A3, CTGF, CYP1B1, DLC1, FBLN1, FBLN5, FGF2, FGFR1, FN1, HAS2, LUM, MMP2, MYL9, NID2, NR2F1, NRP1, PLAT, PPAP2B, PRKCA, RECK, SERPINE1, SERPINE2, SPOCK1, TGM2, TNFAIP6, TPM1, VCAN, WNT5A                                  CD24, CDH1, CXADR, CXCL16, DSG3, ELF3, EPCAM, EPHA, JUP, MPZL2, OVOL2, PLXNB1, S100P, SLC7A5, SYK
  **Development, cell differentiation and proliferation**                                                                     CDKN2C, EMP3, FBN1, IGFBP3, IL1R1, LTBP1, MME, PMP22, PTGER2, PTX3, SRGN, SULF1, SYNE1, TAGLN, TUBA1A, VIM, ZEB1                                                                    ABLIM1, ADRB2, ALDH1A3, ANK3, BIK CA2, CTSL2, FGFR2, FGFR3, FST, GJB3, IFI30, IL18, KLK7, KRT15, KRT17, LSR, MAP7, MBP, OCLN, PKP2, PPL, PRSS8, RAPGEF5, SPINT1
  **Angiogenesis and wound healing**                                                                                                                                           DCN, LOX, TFPI                                                                                                                                                                 *no gene with a major classification* [\*](#nt107){ref-type="table-fn"}
  **Metabolism**                                                                                                                                                          ABCA1, GALNT10, SLC22A4                                                                                                                                                                            GPX3, SLC27A2, SMPDL3B, SORL1, ST6GALNAC2
  **Others or unclassified**                                                                                                                          C5orf13, CDK14, EML1, FSTL1, LTBP2, MAP1B, RGS4, SYT11, TMEM158                                                                                                           AGR2, C10orf10, CDS1, FAM169A, FXYD3, KLK10, LAD1, MTUS1, PLS1, PRRG4, RHOD, SERPINB1, SLPI, TMEM30B, TPD52L1, TSPAN1, ZHX2, ZNF165

Categories have been chosen according to the GO classifications of the enrichment tools. Genes may be present in more than one category.

see [Table S3](#pone.0051136.s006){ref-type="supplementary-material"} for more information.

Consistently enriched KEGG pathway and GO term analysis of the EMT-core gene list {#s2d}
---------------------------------------------------------------------------------

To further analyze the EMT-core list consisting of 130 genes, a rigorous single enrichment analysis combined with stringent selection criteria was performed. First, an enriched KEGG pathway or GO term had to contain at least 5 genes from the input list and a p-value below 0.05 to be considered significant. An enumeration of significantly enriched terms and pathways is shown in [Table 3](#pone-0051136-t003){ref-type="table"}. Second, a significantly enriched KEGG pathway or GO term had to be observed in at least 4 out of 5 used bioinformatic tools. Third, a consistently enriched KEGG pathway or GO term had to be identified in both the EMT-core gene list and the 365 gene list. Using these criteria, we obtained 6 KEGG pathways, 20 GO biological processes and 15 GO molecular functions consistently enriched in both lists ([Table 4](#pone-0051136-t004){ref-type="table"}). The KEGG pathways consisted of the MAPK signaling pathway, axon guidance, focal adhesion, ECM-receptor interaction, regulation of actin cytoskeleton and pathways in cancer. The GO biological processes could be grouped into processes involved in tissue development, wound healing, cell migration or cell proliferation. The GO molecular functions consisted of ECM and cytoskeleton constituents, peptidase inhibitors and the binding of collagen, growth factors, heparin and integrin. As expected, the list with 365 genes comprised all significantly enriched pathways and GO terms from the 130 genes EMT-core list except for 2 GO biological processes (ECM organization and lung development). Several more KEGG pathways, GO biological processes and molecular functions could be identified in the list with 365 genes ([Table 3](#pone-0051136-t003){ref-type="table"} and [4](#pone-0051136-t004){ref-type="table"}). All these pathways, biological processes and molecular functions are well known to be involved in EMT [@pone.0051136-Kalluri1], [@pone.0051136-Yilmaz1]--[@pone.0051136-Hanahan1], and thus confirm the integrity of our EMT-core gene list. In addition, both the EMT-core list and the list with 365 genes display comparable enrichment ratios of KEGG pathways and GO biological processes ([Figure 3](#pone-0051136-g003){ref-type="fig"}) as well as GO molecular functions ([Figure S2](#pone.0051136.s002){ref-type="supplementary-material"}). Therefore, the list containing 365 genes may be considered as an amelioration of the EMT-core list by containing additional genes that might have an ambiguous role in EMT. In summary, our EMT-core list of 130 genes and its amelioration containing 365 genes show strong enrichment of EMT-relevant processes.

![The 130 genes EMT-core list and the 365 genes list exhibit comparable enrichment ratios of GO biological processes and KEGG pathways.\
The enrichment ratio is the number of observed genes divided by the number of expected genes for a given term or pathway. Enrichment ratios were obtained from WebGestalt or calculated with data from FatiGO. GO, gene ontology; BP, biological process; KEGG, Kyoto encyclopedia of genes and genomes.](pone.0051136.g003){#pone-0051136-g003}

10.1371/journal.pone.0051136.t003

###### Number of enriched terms and pathways in all lists detected by the enrichment tools.

![](pone.0051136.t003){#pone-0051136-t003-3}

  Tool               130 gene list   365 gene list   GSE13195 core list   GSE24202 core list                                     
  ----------------- --------------- --------------- -------------------- -------------------- ---- ---- ---- ---- --- ----- ---- ----
  ConsensusPathDB         305             31                 9                   558           61   31   62   10   6   247   34   8
  FatiGO                  178             28                 9                   452           72   36   0    0    2   172   28   10
  GeneCodis               34              16                 8                   155           45   46   59   17   4   240   48   7
  ToppFun                 241             21                 1                   610           45   5    0    0    1   127   14   0
  WebGestalt              40              28                 6                    40           40   37   5    4    4   40    30   8

The numbers of enriched terms and pathways found by the particular enrichment tools are displayed. BP, GO biological process; MF, GO molecular function; KEGG, KEGG pathway. GSE13195 core list of Choi *et al.*, GSE24202 core list of Taube *et al.* [@pone.0051136-Taube1], [@pone.0051136-Choi1].

10.1371/journal.pone.0051136.t004

###### Consistently enriched GO terms and KEGG pathways and their occurrence in the analyzed gene lists.

![](pone.0051136.t004){#pone-0051136-t004-4}

  Term ID                                              Category                           Term size[\*](#nt109){ref-type="table-fn"}   130 gene list   365 gene list   GSE13915 core list   GSE24202 core list               
  --------------------------- ---------------------------------------------------------- -------------------------------------------- --------------- --------------- -------------------- -------------------- --- ---- --- ----
  **GO biological process**                                                                                                                                                                                                  
  GO:0048646                   anatomical structure formation involved in morphogenesis                      390                             4              24                 4                    62           0   \-   4   22
  GO:0001525                                         angiogenesis                                            189                             4              16                 4                    38           0   \-   4   14
  GO:0007596                                      blood coagulation                                          182                             4              13                 4                    29           0   \-   3   13
  GO:0001568                                   blood vessel development                                      288                             4              25                 5                    54           0   \-   5   20
  GO:0007155                                        cell adhesion                                            953                             5              36                 5                    76           2   19   5   41
  GO:0016049                                         cell growth                                             226                             4              13                 4                    34           0   \-   4   14
  GO:0016477                                        cell migration                                           405                             5              32                 5                    67           1   13   5   35
  GO:0048870                                        cell motility                                            484                             4              33                 4                    69           1   13   5   35
  GO:0006928                                 cellular component movement                                     666                             4              36                 5                    73           1   16   5   41
  GO:0009790                                      embryo development                                         619                             4              18                 4                    46           0   \-   3   20
  GO:0008544                                    epidermis development                                        218                             5              16                 4                    32           2   6    5   26
  GO:0007507                                      heart development                                          230                             5              15                 4                    28           1   6    3   10
  GO:0009887                                     organ morphogenesis                                         800                             5              21                 5                    54           0   \-   5   34
  GO:0042127                               regulation of cell proliferation                                  823                             4              28                 5                    81           1   14   5   37
  GO:0050793                             regulation of developmental process                                 1005                            4              34                 4                    88           0   \-   4   32
  GO:0009611                                     response to wounding                                        776                             5              31                 5                    85           0   \-   4   34
  GO:0001501                                 skeletal system development                                     394                             4              14                 4                    35           0   \-   5   20
  GO:0009888                                      tissue development                                         808                             4              38                 4                    93           1   12   5   52
  GO:0001944                                   vasculature development                                       294                             4              25                 4                    56           0   \-   5   20
  GO:0042060                                        wound healing                                            270                             4              20                 5                    50           0   \-   3   19
  **GO molecular function**                                                                                                                                                                                                  
  GO:0005509                                     calcium ion binding                                         1033                            4              22                 4                    55           0   \-   4   34
  GO:0030246                                     carbohydrate binding                                        380                             4              15                 4                    29           1   7    4   14
  GO:0005518                                       collagen binding                                           40                             4               5                 5                    12           0   \-   0   \-
  GO:0004866                               endopeptidase inhibitor activity                                  179                             4               9                 4                    19           0   \-   4   9
  GO:0004857                                  enzyme inhibitor activity                                      327                             4              10                 4                    26           2   8    4   13
  GO:0005201                                       ECM constituent                                           105                             5               7                 5                    12           0   \-   4   7
  GO:0005539                                  glycosaminoglycan binding                                      146                             4              13                 5                    24           0   \-   5   10
  GO:0019838                                    growth factor binding                                        127                             4              13                 4                    26           0   \-   5   14
  GO:0008201                                       heparin binding                                           108                             4               9                 4                    17           0   \-   3   7
  GO:0005178                                       integrin binding                                           57                             4               6                 5                    9            0   \-   4   7
  GO:0030414                                 peptidase inhibitor activity                                    192                             5               9                 5                    20           0   \-   4   9
  GO:0030247                                    polysaccharide binding                                       165                             4              14                 4                    27           0   \-   5   13
  GO:0032403                                   protein complex binding                                       199                             4              11                 4                    20           0   \-   2   8
  GO:0004867                         serine-type endopeptidase inhibitor activity                            118                             4               9                 4                    14           0   \-   3   7
  GO:0005200                            structural constituent of cytoskeleton                                92                             5               8                 5                    10           0   \-   5   13
  **KEGG pathway**                                                                                                                                                                                                           
  map04360                                          axon guidance                                            126                             4               6                 4                    11           0   \-   4   6
  map04512                                     ECM-receptor interaction                                       92                             5               7                 5                    18           0   \-   1   5
  map04510                                          focal adhesion                                           207                             4               9                 5                    23           0   \-   3   8
  map04010                                      MAPK signaling pathway                                       289                             3               7                 4                    15           0   \-   0   \-
  map05200                                        pathways in cancer                                         329                             4              11                 5                    28           1   5    2   8
  map04810                                 regulation of actin cytoskeleton                                  209                             4               7                 4                    16           0   \-   2   6

According to FatiGO category size in genome.

The maximum number of genes from the category present in the input list is displayed. ID, identity; GO, gene ontology; KEGG, Kyoto encyclopedia of genes and genomes. GSE13195 core list of Choi *et al.*, GSE24202 core list of Taube *et al.* [@pone.0051136-Taube1], [@pone.0051136-Choi1].

Clinical relevance of the EMT-core gene list {#s2e}
--------------------------------------------

The EMT-core gene list contains several genes with yet unidentified roles in cancer progression and/or EMT. We aimed to investigate the clinical relevance of this selection of genes. Therefore, we correlated their expression with overall survival of patients suffering from squamous cell lung carcinomas (SCC) [@pone.0051136-Raponi1] and pathological complete response (pCR) of breast cancer patients [@pone.0051136-Hess1]. From the downregulated genes of the EMT-core gene list, low FXYD3 expression showed a trend to poor overall survival of SCC patients (p = 0.17) and low expression of LAD1 (p = 0.00074), SLC7A5 (p = 0.0093) and SLPI (p = 0.043) significantly correlated with worse pCR of breast cancer patients. From the upregulated genes of the EMT-core gene list, high PTX3 expression tends to poor overall survival of SCC patients (p = 0.16) and high expression of NID2 (p = 0.0091), SPOCK1 (p = 0.038) and SULF1 (p = 0.00029) significantly correlated with impaired pCR of breast cancer patients. These correlations demonstrate that the comparison of different data sets is a powerful tool to identify novel relevant target genes that do not emerge from single studies.

Discussion {#s3}
==========

Over the past decade a considerable number of GES that deal with EMT have been accumulating in the literature. These cover a variety of cell types which display EMT and include different modes of EMT induction. So far, these resources have only been partially used to compare single findings with those in the literature [@pone.0051136-Tobin1], [@pone.0051136-Hwang1], [@pone.0051136-Micalizzi1]. To our knowledge, no attempt has been made to investigate the majority of the independent GES of EMT for their relations to each other. Although we are aware that gene expression data of EMT are not complete, we analyzed the currently available GES to generate an EMT-core list of genes altered most frequently during the EMT process, as depicted in the flow chart ([Figure S3](#pone.0051136.s003){ref-type="supplementary-material"}).

Cluster analysis of genes shared between at least 10 GES datasets revealed clusters of GES with the same or a similar treatment type. The GES in which EMT was induced by TNF-α either alone or in combination with TGF-β, by TGF-β alone or by different transcription factors consistently grouped together. These clusters persisted when genes shared between at least 14 datasets were used for cluster analysis. A clear clustering of different types of EMT induction, however, would have only been possible if an adequate number of GES on each of these EMT initiation methods existed. Since several treatment modalities are only represented once in the literature, such GES cluster to their most related treatment type.

One cluster predominantly emerged from GES of TGF-β-induced EMT which consisted of 13 datasets. Interestingly, the cluster includes the exogenous expression of Six1 (Micalizzi *et al*; GSE23655; [@pone.0051136-Micalizzi1]) which has been shown to enhance tumor-promoting TGF-β signaling, and Runx2 (Baniwal *et al*; GSE24261; [@pone.0051136-Baniwal1]) that acts downstream of TGF-β signaling [@pone.0051136-Micalizzi2]--[@pone.0051136-Chimge1]. Hence, this supports the clustering of these studies together with others using TGF-β as EMT initiator. The study by van Zijl *et al.* (GSE26391; [@pone.0051136-vanZijl2]) described the analysis of epithelial and mesenchymal hepatocellular carcinoma cells derived from the same tumor patient. The clustering of this study along with other studies with TGF-β-induced EMT suggests an involvement of TGF-β signaling during the establishment of the mesenchymal cell line.

The cluster of GES with TNF-α as EMT inducer contained the study by Takahashi *et al.* which analyzed the ARPE19 cell line treated with either TNF-α alone (GSE15205_TNFa), TNF-α together with TGF-β (GSE12548) or TGF-β alone (GSE15205_TGFb) in order to induce EMT [@pone.0051136-Takahashi1]. The two datasets with TNF-α treatment formed a consistent cluster. However, the third dataset which was obtained from the exclusive treatment with TGF-β clustered to other GES describing EMT initiation by TGF-β. Hence, these data suggest a stronger impact of the EMT stimulus on the clustering rather than the cell type.

One cluster consisted mainly of the datasets from Taube *et al.* (GSE24202; [@pone.0051136-Taube1]) who reported the induction of EMT in HMLE cells using overexpression of Twist, Snail, Goosecoid and TGF-β as well as the knockdown of E-cadherin. Consistent with the data reported by Taube *et al*, the datasets from Snail- and Twist-induced EMT were the most similar within this cluster. This finding is concordant with the fact that Twist is a direct target of Snail [@pone.0051136-Ip1]. The high number of datasets in this study might lead to an overrepresentation within the cluster analysis. Furthermore, the use of the same cell line as well as transcription factors with similar targets such as Twist and Snail might lead to a high level of similarity within the datasets of this particular study.

The cluster comprising of Ke *et al.* (E-TABM-949; [@pone.0051136-Ke1]) who utilized high cell density culturing of EPT2 cells and Ohashi *et al.* (GSE27424; [@pone.0051136-Ohashi1]) who described a NOTCH3 knock-down in EPC2 cells displays a low level of relation to other clusters due to the unique types of EMT induction. It appears likely that on the one hand these GES form a cluster due to the lack of relationship to the other clusters. On the other hand, it might also suggest a relation of their types of EMT initiation as well.

We found a variety of well-known markers of EMT upregulated in our EMT-core gene list such as CDH2, CDH11, COL1A1, COL3A1, FBLN5, FN1, HAS2, LOX, MMP2, PLAT, SERPINE1, VIM, WNT5A and ZEB1 [@pone.0051136-Zeisberg1], [@pone.0051136-ZoltanJones1], [@pone.0051136-Ren1]. Furthermore, we detected downregulated genes reported to be reduced in EMT such as ANK3, CDH1, CXADR, PRSS8 and SYK [@pone.0051136-Zeisberg1], [@pone.0051136-Kumar1]--[@pone.0051136-Sung1], several downregulated epithelial cell markers such as EPCAM, JUP, KRT15, KRT17, OCLN, PKP2 and PPL [@pone.0051136-Kalluri1], [@pone.0051136-Zeisberg1] and a number of downregulated tumor suppressors such as KLK10, MTUS1, OAS1 and SERPINB1 [@pone.0051136-Talieri1]--[@pone.0051136-Chou1]. Together, these genes provide a solid verification of our EMT-core gene list. Besides those genes confirming the integrity of our gene list, however, genes with unknown functions as well as an unknown or unclear relation to cancer and/or EMT emerged which are novel candidates for further investigation. Upregulated genes include MAP1B, NID2, PTX3, SPOCK1, SULF1, TAGLN and TMEM158 while downregulated genes comprised ABLIM1, LAD1, FAM169A, FXYD3, SLC7A5, SLPI, TMEM30B and TPD52L1.

Two meta-analyses of EMT in breast cancer considering different cell lines or types of EMT induction have been reported. These have identified EMT-core gene lists with 200 and 251 genes [@pone.0051136-Taube1], [@pone.0051136-Choi1], however, overlapping with approximately 10% only. Our EMT-core list containing 130 genes shows a poor overlap of 7% with the list of Choi *et al.* [@pone.0051136-Choi1] but an overlap of 55% with Taube *et al.* [@pone.0051136-Taube1]. Both the lists by Choi *et al.* and Taube *et al.* contain unmapped identifiers (IDs) such as array IDs, expressed sequence tags and locus IDs. We used consistently enriched pathway analysis to further investigate these gene lists. Notably, our EMT-core list displayed more enriched KEGG pathways and GO terms than the gene lists of Choi *et al.* and Taube *et al.* ([Table 3](#pone-0051136-t003){ref-type="table"} and [4](#pone-0051136-t004){ref-type="table"}). Upon reducing the stringency of analysis to two genes within an enriched category, the enrichment for the list of Choi *et al.* did not improve whereas nearly all KEGG pathways and GO terms enriched in our EMT-core list could be observed in the list of Taube *et al.* (data not shown, [Table 4](#pone-0051136-t004){ref-type="table"}).

The EMT-core list contains several genes with unknown functions and relations to cancer and/or EMT. We were able to show that FXYD3 and PTX3 expression is associated with poor overall patient survival in SCC patients and LAD1, SLC7A5, SLPI, NID2, SPOCK1 and SULF1 correlated significantly with impaired pCR in breast cancer patients. FXYD3 has been shown to be involved in tumor cell proliferation and to be downregulated by TGF-β signaling [@pone.0051136-Yamamoto1], [@pone.0051136-Yamamoto2]. PTX3 has been reported to be a lung cancer biomarker [@pone.0051136-Diamandis1]. NID2 has been shown to be elevated during phorbol 12-myristate 13-acetate-induced invasion of several human tumor cell lines and as a potential tumor biomarker [@pone.0051136-Rouleau1], [@pone.0051136-Kuk1]. SPOCK1 has been reported to be involved in neuronal attachment and matrix metalloproteinase activation [@pone.0051136-Marr1], [@pone.0051136-Nakada1]. SULF1 has been shown to be a potential biomarker for gastric cancer which can be induced by TGF-β1 [@pone.0051136-Junnila1], [@pone.0051136-Yue1]. LAD1 is an adaptor protein involved in ERK5 and JNK pathways [@pone.0051136-Sun1]. SLPI has been reported to act anti-tumorigenic for certain tumors as well as to promote migration and invasion in others [@pone.0051136-Wen1]--[@pone.0051136-Choi2]. Hence, these genes seem to be promising candidates for further investigation. Taken together, we propose that the EMT-core list of 130 genes is highly relevant for EMT and the cluster analysis represents a useful overview on the relationships of currently available GES of EMT.

Materials and Methods {#s4}
=====================

Data collection and annotation {#s4a}
------------------------------

Processed microarray data were downloaded from the websites of GEO (available: <http://www.ncbi.nlm.nih.gov/geo/>) and AE (available: <http://www.ebi.ac.uk/arrayexpress/>) by using "EMT" as keyword for published GES until February 2012. The downloaded GES were annotated to retrieve official gene symbols, EntrezID and gene names using BioConductor 2.9 (available: <http://www.bioconductor.org/>; accessed: 2012 Jan 02) [@pone.0051136-Gentleman1] and the online tool NetAffx (available: <http://www.affymetrix.com/analysis/index.affx>; accessed: 2012 June 25). BioConductor was used within the R environment [@pone.0051136-R1]. Annotated data was imported to MS-Excel 2010 and log2 transformed. Subsequently, fold changes and p-values using two-sided Student\'s *t*-test were calculated. Significantly up- and downregulated genes were selected and separated from each other when showing a fold change greater than 2 or below 0.5 and a p-value below 0.05. Upregulated genes were ordered from highest to lowest fold change. Vice versa, downregulated genes were arranged from lowest to highest fold change. Duplicates were removed afterwards. Gene symbols have been used for further analysis and will be referred to as genes.

Cluster analysis {#s4b}
----------------

The up- and downregulated genes from each study were summarized, ordered and duplicates were removed to obtain a list of all uniquely reported genes across all studies. Upregulated genes were labeled with 1 and downregulated genes were labeled with −1. Genes that were not significantly deregulated within a GES and genes which were found to be both up- and downregulated within a study were labeled with 0. The distribution of the observed number of up- and downregulated genes was tested against a binomial distribution with parameter p = 11.78% by means of a chi-squared test. We calculated the possibilities of drawing each cutoff option for cluster analysis (\>1, \>2, \>3, and so forth) by chance with the binomial distribution function provided by R (probability = 11.78%). The possibilities to draw each cutoff option by chance were compared to preliminary cluster analyses of each cutoff option in order to determine a suitable cutoff. The clustering was performed in BioConductor 2.9 embedded in R 2.14.1 (64 bit) with the packages gdata [@pone.0051136-Warnes1], gplots [@pone.0051136-Warnes2] and heatmap.plus [@pone.0051136-Day1] using hierarchical heatmap clustering with Manhattan distance function.

Consistently enrichment of KEGG pathways and GO terms {#s4c}
-----------------------------------------------------

The gene lists were analyzed using five different bioinformatic enrichment tools. A comprehensive overview of the used tools and their characteristics is shown in [Table S4](#pone.0051136.s007){ref-type="supplementary-material"}. The tools FatiGO and GeneCodis were used on the Babelomics 4 platform [@pone.0051136-Medina1], which provided access to both programs at once. The selection criteria for significantly enriched pathways were a p-value or FDR below 0.05 and a minimum of 5 genes of the input list within an enriched category. Furthermore, consistently enriched GO terms and KEGG pathways were identified in at least 4 of 5 programs in both the EMT-core gene list and the 365 gene list. Enrichment ratios (number of observed genes divided by the number of expected genes for a GO or KEGG category) have been obtained by WebGestalt, or alternatively, have been calculated as described by Zhang *et al.* with the data from FatiGO [@pone.0051136-Zhang1].

Correlation of the EMT-core list with clinical data {#s4d}
---------------------------------------------------

Microarray and clinical data for patients with squamous cell lung carcinomas (n = 130) reported by Raponi *et al.* [@pone.0051136-Raponi1] with the accession GDS2373 were downloaded from GEO. Microarray and clinical data for breast cancer patients (n = 133) reported by Hess *et al.* [@pone.0051136-Hess1] were downloaded from the MD Anderson Cancer Center website (available: <http://bioinformatics.mdanderson.org/pubdata.html>; accessed 2012 Sep 07). Patients were divided into high and low expressing groups for selected genes within the EMT-core list. The p-values were computed using two-sided Student\'s *t*-test. Survival analysis for the data by Raponi *et al.* was performed with the chi-squared test of equality using the survival package in R [@pone.0051136-Thernau1]. P-values below 0.05 were considered significant.
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